CD274 and non-small cell lung carcinoma: In particular, the development of specific antibodies against the programmed death (PD-1) receptor, programmed death-ligand 1 (PD-L1), and the cytotoxic T-lymphocyte-associated protein 4 receptor in the therapeutic strategy of NSCLC either in first- or in second-line settings have led to unprecedented, prolonged survival for a proportion of these patients [12].